Despite remarkable outcome results, patients receiving EGFR-TKIs usually developed secondary resistance after approximately 9 to 13 months (median PFS: 9–12 months) and showed major adverse events grade 3 or higher, including diarrhea, rash or acne, and stomatitis or mucositis.[16–18]. This evidence concerns the gene EGFR and stomatitis.